Mutz Christopher

SEC source: 0001846487-26-000014 · wk-form4_1773437295.xml · nonDerivative · entry 1

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 91,309

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.

F2 · price: The shares were sold in multiple trades at prices ranging from $70.27 to $72.62. The price reported above reflects the weighted average sales price.

SEC source: 0001846487-26-000012 · wk-form4_1773173381.xml · nonDerivative · entry 3

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 94,471

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.

F4 · price: The shares were sold in multiple trades at prices ranging from $73.27 to $74.81. The price reported above reflects the weighted average sales price.

SEC source: 0001846487-26-000012 · wk-form4_1773173381.xml · nonDerivative · entry 2

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 98,073

F3 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 6,476 shares of restricted stock, the grant of which was previously reported.

SEC source: 0001846487-26-000012 · wk-form4_1773173381.xml · nonDerivative · entry 1

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 101,387

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.

F2 · price: The shares were sold in multiple trades at prices ranging from $73.14 to $75.00. The price reported above reflects the weighted average sales price.

SEC source: 0001846487-26-000010 · wk-form4_1772668004.xml · nonDerivative · entry 1

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,508

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.

SEC source: 0001846487-26-000008 · wk-form4_1772492353.xml · nonDerivative · entry 2

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 103,925

F2 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,342 shares of restricted stock, the grant of which was previously reported.

SEC source: 0001846487-26-000008 · wk-form4_1772492353.xml · nonDerivative · entry 1

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 106,146

F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026.

SEC source: 0001846487-26-000006 · wk-form4_1771885908.xml · nonDerivative · entry 1

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 84,840

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.

F2 · price: The shares were sold in multiple trades at prices ranging from $77.20 to $78.58. The price reported above reflects the weighted average sales price.

SEC source: 0001846487-26-000004 · wk-form4_1771362479.xml · nonDerivative · entry 3

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 90,163

F4 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,697 shares of restricted stock, the grant of which was previously reported on February 16, 2024.

SEC source: 0001846487-26-000004 · wk-form4_1771362479.xml · nonDerivative · entry 2

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 92,566

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.

F3 · price: The shares were sold in multiple trades at prices ranging from $75.43 to $76.92. The price reported above reflects the weighted average sales price.

SEC source: 0001846487-26-000004 · wk-form4_1771362479.xml · nonDerivative · entry 1

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 99,598

F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 6,202 shares of restricted stock, the grant of which was previously reported on February 18, 2025.

SEC source: 0001846487-26-000002 · wk-form4_1771016933.xml · nonDerivative · entry 1

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 102,771

F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 11,578 performance stock units, the grant of which was previously reported on April 6, 2023.

SEC source: 0001846487-25-000008 · wk-form4_1747354237.xml · nonDerivative · entry 1

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,317

SEC source: 0001846487-25-000006 · wk-form4_1741987349.xml · nonDerivative · entry 1

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 111,317

F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 6,476 shares of restricted stock, the grant of which was previously reported.

SEC source: 0001846487-25-000004 · wk-form4_1741126332.xml · nonDerivative · entry 1

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 114,191

F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,342 shares of restricted stock, the grant of which was previously reported.

SEC source: 0001846487-25-000002 · wk-form4_1739927844.xml · nonDerivative · entry 4

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 115,466

F4 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,034 shares of restricted stock, the grant of which was previously reported.

SEC source: 0001846487-25-000002 · wk-form4_1739927844.xml · nonDerivative · entry 3

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 116,650

F3 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,697 shares of restricted stock, the grant of which was previously reported.

SEC source: 0001846487-25-000002 · wk-form4_1739927844.xml · nonDerivative · entry 2

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 118,123

F2 · kind: These shares represent performance stock units, which will vest over the applicable performance period based on the achievement of the provided performance targets, as set forth in the governing award agreement, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting.

SEC source: 0001846487-25-000002 · wk-form4_1739927844.xml · nonDerivative · entry 1

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 101,585

F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 12, 2025.

SEC source: 0001846487-24-000014 · wk-form4_1731963799.xml · nonDerivative · entry 1

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,777

SEC source: 0001846487-24-000012 · wk-form4_1716416059.xml · nonDerivative · entry 1

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,277

SEC source: 0001846487-24-000010 · wk-form4_1709864200.xml · nonDerivative · entry 1

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,277

F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 6,476 shares of restricted stock, the grant of which was previously reported.

SEC source: 0001846487-24-000008 · wk-form4_1709760262.xml · nonDerivative · entry 1

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,387

F1 · price: The shares were sold in multiple trades at prices ranging from $65.77 to $66.49. The price reported above reflects the weighted average sales price.

SEC source: 0001846487-24-000006 · wk-form4_1709331156.xml · nonDerivative · entry 1

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,387

F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,342 shares of restricted stock, the grant of which was previously reported.

SEC source: 0001846487-24-000004 · wk-form4_1708466458.xml · nonDerivative · entry 1

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,662

F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,034 shares of restricted stock, the grant of which was previously reported.

SEC source: 0001846487-24-000002 · wk-form4_1708120221.xml · nonDerivative · entry 2

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 94,923

F2 · kind: These shares represent performance stock units, which will vest over the applicable performance period based on the achievement of the provided performance targets, as set forth in the governing award agreement, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting.

SEC source: 0001846487-24-000002 · wk-form4_1708120221.xml · nonDerivative · entry 1

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,397

F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 14, 2024.

SEC source: 0001846487-23-000003 · wk-form4_1699909333.xml · nonDerivative · entry 1

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,607

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $52.41 to $52.58, inclusive.

SEC source: 0001104659-23-030710 · tm239061-5_4seq1.xml · nonDerivative · entry 2

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,660

F2 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 1,619 shares of restricted stock, the grant of which was previously reported.

SEC source: 0001104659-23-030710 · tm239061-5_4seq1.xml · nonDerivative · entry 1

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,136

F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,857 shares of restricted stock, the grant of which was previously reported.

SEC source: 0001104659-23-041738 · tm2311710-7_4seq1.xml · nonDerivative · entry 2

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,607

F2 · kind: These shares represent performance stock units, which will vest over the applicable performance period based on the achievement of the provided performance targets, as set forth in the governing award agreement, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting.

SEC source: 0001104659-23-041738 · tm2311710-7_4seq1.xml · nonDerivative · entry 1

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,029

F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 28, 2023.

SEC source: 0001104659-23-023305 · tm237192-2_4seq1.xml · nonDerivative · entry 1

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,562

SEC source: 0001415889-22-004411 · form4-04292022_030430.xml · nonDerivative · entry 1

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,854

F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of March 7, 2022.

SEC source: 0001415889-22-003396 · form4-03282022_050322.xml · nonDerivative · entry 1

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,378

F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of March 7, 2022.

SEC source: 0001415889-22-001535 · form4-02172022_040230.xml · nonDerivative · entry 1

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,950

F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,033 shares of restricted stock, the grant of which was previously reported.

SEC source: 0001415889-21-000745 · form4-02172021_060228.xml · derivative · entry 2

Mutz Christopher · CIK 0001846487 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,758

Underlying: Common Stock · 33,758 shares

Expires 2031-02-15

F2 · derivative.exercise_date: The option will vest and become exercisable as to 25% of the total shares on each of February 15, 2022, February 15, 2023, February 15, 2024 and February 15, 2025.

SEC source: 0001415889-21-000745 · form4-02172021_060228.xml · nonDerivative · entry 1

Mutz Christopher · CIK 0001846487 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,134

F1 · shares: Represents a restricted stock award that will vest as to 25% of the total shares on each of February 15, 2022, February 15, 2023, February 15, 2024 and February 15, 2025.